Reuters logo
BRIEF-Albireo announces plans for Phase 3 clinical program of A4250 in patients with PFIC
May 18, 2017 / 12:24 PM / 4 months ago

BRIEF-Albireo announces plans for Phase 3 clinical program of A4250 in patients with PFIC

May 18 (Reuters) - Albireo Pharma Inc

* Albireo announces plans for Phase 3 clinical program of A4250 in patients with PFIC

* Albireo Pharma Inc says initiation of Phase 3 anticipated in second half of 2017

* Albireo Pharma - planned Phase 3 PFIC program includes single randomized, double blind, placebo controlled, multicenter, six-month treatment trial

* Albireo Pharma - planned Phase 3 PFIC program trial designed to enroll 60 patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below